Loading stock data…
Protagonist Therapeutics (PTGX)
$136.11+0.68 (+0.50%)
Market ClosedLast close Jul 24
Protagonist Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protagonist Therapeutics, Inc. in the Healthcare sector is trading at $136.11 with a market capitalization of $7.1B. Wall Street consensus targets $133.31 (13 analysts), implying a -2.1% move over the next 12 months. The stock is currently near its 52-week high of $143.29, remaining 42.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $56.37M↑ | $7.44M↑ | $4.71M↓ | $5.55M↓ | $28.32M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.65M↑ | -$50.35M↓ | -$46.42M↓ | -$42.04M↓ | -$19.31M |
| Net Income | $3.78M↑ | -$44.38M↓ | -$39.34M↓ | -$34.77M↓ | -$11.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and ol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.50%
Volume
Today's trading volume
274,404
Recent News
Best Momentum Stocks to Buy for July 13th
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
New Strong Buy Stocks for July 13th
FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review
After a very large three year return, Protagonist Therapeutics now faces a valuation debate, with the stock’s strong share price performance sitting alongside a mixed read from the latest valuation checks. Over three years, Protagonist Therapeutics has delivered a return of roughly 7x, which puts extra focus on whether the current price already builds in much of the good news. The launch of Icotyde and the FDA priority review for rusfertide can support higher revenue expectations, while...
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued
Protagonist Therapeutics (PTGX) has been in focus after two key milestones: the FDA approval and U.S. launch of Icotyde for psoriasis, and a priority review for rusfertide in polycythemia vera with an August 2026 decision expected. See our latest analysis for Protagonist Therapeutics. Protagonist Therapeutics’ share price has surged in recent months, with a 60.67% year to date share price return and a very large 3 year total shareholder return, as investors focus on Icotyde’s launch and...
New Strong Buy Stocks for July 9th
PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.